Cardiovascular Pharmacologists explore the use of medications to treat and manage heart and blood vessel disorders. Their work centers on investigating how different drugs interact with the cardiovascular system, aiming to improve therapies for conditions such as hypertension, heart failure, arrhythmias, and ischemic heart disease. By studying the effects of drugs on heart tissues and blood flow, these specialists uncover how medications can restore balance to cardiovascular function. They explore new compounds, test their efficacy, and assess how these drugs can be used to prevent or reduce the progression of disease. Their research helps identify potential breakthroughs in drug development for heart disease.
In both research and clinical settings, they focus on how medications can be best used in patient care, evaluating dosage, response, and potential side effects. This exploration includes analyzing drug mechanisms, absorption rates, and interactions with other treatments. Their findings support the development of targeted therapies and safer prescribing practices. Cardiovascular pharmacologists collaborate with healthcare providers, regulatory bodies, and pharmaceutical companies to bring new treatments from the lab to the clinic. Through their dedication to exploring how drugs affect the heart, they contribute to advancing cardiovascular medicine, enhancing patient outcomes, and refining the way heart conditions are treated with modern pharmacological tools.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India